

UHL Research and Innovation: 2016-17 quarter 1 report

Author: Professor N Brunskill Sponsor: Andrew Furlong Trust Board 7 July 2016 Trust Board paper J

Executive Summary

Context

UHL is a Trust active in Research and Innovation (R&I). This report describes current R&I performance against metrics, projects under development, new challenges and potential threats.

Questions

1. Is UHL performing well in the delivery of quality research at expected volume?
2. Are large projects planned with appropriate partners and managed appropriately?
3. Are upcoming challenges understood?

Conclusion

1. UHL performs well in delivering high quality research as judged by NIHR and LCRN data.
2. A larger number of large projects are in development, some being close to start date. There is a wide range of NHS and Academic partner engagement.
3. A number of challenges are recognised and planning is in place to mitigate risks.

Input Sought

Report is presented for information.

For Reference

Edit as appropriate:

1. The following objectives were considered when preparing this report:

Safe, high quality, patient centred healthcare	[Yes]
Effective, integrated emergency care	[Yes]
Consistently meeting national access standards	[Not applicable]
Integrated care in partnership with others	[Yes]
Enhanced delivery in research, innovation & ed'	[Yes]
A caring, professional, engaged workforce	[Yes]
Clinically sustainable services with excellent facilities	[Yes]
Financially sustainable NHS organisation	[Yes]
Enabled by excellent IM&T	[Yes]

2. This matter relates to the following governance initiatives:

Organisational Risk Register	[Yes]
Board Assurance Framework	[Yes]

3. Related Patient and Public Involvement actions taken, or to be taken: [Insert here]

4. Results of any Equality Impact Assessment, relating to this matter: n/a

5. Scheduled date for the next paper on this topic: [October 2016 Trust Board]

6. Executive Summaries should not exceed 1page. [My paper does comply]

7. Papers should not exceed 7 pages. [My paper does comply]

UHL R&I Quarterly Trust Board Report July 2016

1. Introduction

This report describes current R&I performance against metrics, projects under development, new challenges and potential threats.

2. Research Performance

The activity of UHL in initiating and delivering clinical research is performance monitored by both the NIHR Central Commissioning Facility (NIHR CCF) and the East Midlands Clinical Research Network (EM CRN). In turn the UHL R&I Office reports research CMG level activity and performance to each CMG via the R&I Executive Committee.

2.1 NIHR CCF.

In Q4 15/16 UHL initiated 99 clinical trials. These figures confirm a stable level of activity.

Table 1: UHL Performance in initiating clinical research trials

	Number of Trials Initiated		
	2013/14	2014/15	2015/16
Q1	111	91	107
Q2	125	79	107
Q3	121	82	116
Q4	116	95	99

UHL is also judged by its performance in recruiting patients into initiated trials within 70 days. In Q4 2015/16 this figure was 75% and represents a sustained improvement. Overall in terms of both initiating and delivering research UHL remains in League 1 (of 7) by NIHR.

2.2. EM CRN.

Recruitment into portfolio clinical trials for 15/16 was 13,479 individuals. This exceeded recruitment for 14/15 when UHL significantly exceeded targets (Table 2). UHL is the highest recruiting trust in the East Midlands by a factor of x2.5 greater than the next highest recruiting Trust.

Table 2: Cumulative Recruitment Numbers of Patients into UHL Studies 2014/15 and 15/16

	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar
Cumulative Recruitment 14/15	950	2047	3007	4079	5314	6224	7282	8363	9169	10223	11266	12564
Cumulative Recruitment 15/16	1078	1946	3112	4112	4972	5961	7477	9327	10112	10923	12546	13479

3. Projects in Development

3.1 New Projects under Development.

3.1.1 NIHR Biomedical Research Centres (BRCs)

UHL, with University of Leicester and Loughborough University as academic partners, was invited to submit a full BRC application. This described three themes: cardiovascular, respiratory, and diet and lifestyle. Precision medicine is the cross-cutting theme. Interviews will be held in later July 2016.

3.1.2 NHIR Renew and Refresh Call for Clinical Research Facility (CRF) Funding

UHL has submitted an application for funding from NIHR to meet the necessary recurrent NHS infrastructure costs and NHS support costs of funded, world-class, early translational research undertaken in existing CRF facilities at UHL. The application requests £5.7M over 5 years to support this activity and is complementary to, but not dependent on, the BRC application.

3.1.3 Renewal of Cancer Research UK (CRUK) Centre

UHL is working with the University of Leicester to support the renewal of the CRUK Centre and the Experimental Cancer Medicine Centre. A draft bid has been submitted and a final bid will be submitted in August 2016. UHL is working to ensure full clinical service and R&I support is in place.

3.2. Existing Projects.

3.2.1. *The 100,000 Genome Project.*

UHL is now delivering recruitment to the rare diseases component of this project to an agreed trajectory. Cancer will begin recruitment in July 2016. Recruitment rates are subject to continuous scrutiny and UHL is making changes to clinical pathways to facilitate.

3.2.2. *Leicester Precision Medicine Institute*

Both Clinical and Commercial Directors are now in place.

4. Innovation/Enterprise Activities

- Optimed Project – wider Trust implementation in progress and UHL working to become East Midlands Hub
- NeedleGuide – a device for safe placement of needles and cannulae. Inventor at UHL working with Loughborough University, Dept. of Engineering to produce prototype device and potential manufacturer has been identified.
- UHL R&L attended Med Tech Fair at Ricoh Arena in Coventry
- EMBER Brethomics project: UHL working with external industry partner to develop paediatric focused product

5. New/Existing Challenges

5.1. Uncertain Renewal of Funding for Major Projects.
(see above)

5.2. UHL Research and Innovation Strategy Refresh.
UHL's R&I strategy is due to be updated in 2016. This will be developed in close collaboration with Academic partners and will depend on outcome of major funding bids.

5.1. Delivery of 100,000 Genome Project.

Recruitment remains under close scrutiny. Working with clinical specialities to facilitate recruitment

5.2 Hope Unit at Glenfield

There is lack of capacity for clinical trials in cancer studies. Efforts continue to identify suitable space for Hope Unit at Glenfield Hospital

Nigel Brunskill
June 2016